ABG Analyst expects significant costs increase at Coloplast

ABG Sundal Collier has lowered its recommendation for Coloplast from "hold" to "sell" as it anticipates that the medtech company's costs will increase considerably in the future.

BY MARKETWIRE OG CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

Published: 06.10.21 at 10:14

Coloplast has had its recommendation lowered to "sell" from "hold" by the investment bank ABG Sundal Collier.

The share price target has also been lowered to DKK 900 (USD 140) from DKK 1141 (USD 177).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

Carb-X secures USD 370m in fight against antibiotic resistance

Aleks Engel, a partner of Novo Holdings’s antimicrobial activities, the Repair Impact Fund | Photo: Novo Holdings / PR

International antibiotic alliance Carb-X has received commitments of up to USD 370m to accelerate the development of new antibiotics to combat a future shortage. The news is welcomed by several players on the AMR field.

Former Ambu CEO's equity investments end in USD 2m losses

Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.

Jesper Høiland retires as chief commercial officer of Ascendis Pharma

Jesper Høiland, outgoing global chief commercial officer of Ascendis Pharma | Foto: Radius Health / PR

Former executive vice president of Novo Nordisk, US, Jesper Høiland has decided to step down from his role as global chief commercial officer at Ascendis Pharma.

ALK finds replacement for long-time North America lead

Nearly 23 years as head of the US at ALK have come to end for Jorge Alderete, who is retiring effective June 30 | Photo: ALK / PR

Jorge Alderete, ALK’s president in North America, is leaving the firm after 23 years. He will be replaced by Hans Lindeberg, ALK’s current head of the Nordic region.

Monkeypox vaccine attracts interest for Bavarian as virus spreads

Bavarian, which signed a supply contract with an unnamed European country last week, reports it is in dialog with several countries, some yet to be affected, concerning the firm’s monkeypox vaccine.

MedWatch

ABG Analyst expects significant costs increase at Coloplast

Read the whole article

Get full access for you and your coworkers.

More from MedWatch

Carb-X secures USD 370m in fight against antibiotic resistance

Former Ambu CEO's equity investments end in USD 2m losses

Jesper Høiland retires as chief commercial officer of Ascendis Pharma

ALK finds replacement for long-time North America lead

Monkeypox vaccine attracts interest for Bavarian as virus spreads

Further reading

Related articles

Latest news

Job